Cervical Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV035 MIFTS: 69	Cervical Cancer Categories: Genetic diseases, Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer ⁵⁷ ³⁸ ¹² ⁷⁶ ⁷⁵ ³⁷ ⁵⁵ ⁴³ ³ ¹⁵ ⁶³ ⁷³

Uterine Cervical Neoplasm ¹² ⁷³

Cervical Cancer, Somatic ⁵⁷ ¹³

Cervix Cancer ¹² ⁷⁵

Neoplasm of Uterine Cervix ¹²

Uterine Cervical Neoplasms ⁴⁴

Tumor of the Cervix Uteri ¹²

Cancer, Cervical, Somatic ⁴⁰

Malignant Tumor of Cervix ⁷³

Uterine Cervical Cancer ⁷⁵

Cervix Uteri Cancer ¹²

Cervical Neoplasm ¹²

Cervix Carcinoma ⁷³

Cerca ⁷⁵

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

Malignant neoplasm: Cervix uteri, unspecified

External Ids:

OMIM ⁵⁷ 603956

Disease Ontology ¹² DOID:4362

ICD10 ³³ C53 C53.9

ICD9CM ³⁵ 180 180.9

MeSH ⁴⁴ D002583

NCIt ⁵⁰ C2940 C9311

SNOMED-CT ⁶⁸ 123841004 188174005 188186008 more

MedGen ⁴² C4048328 C0302592

KEGG ³⁷ H00030

SNOMED-CT via HPO ⁶⁹ 108369006 363346000

UMLS ⁷³ C0007847 C0007873 C4048328

Sources

Summaries for Cervical Cancer

MedlinePlus : ⁴³ The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasm, is related to cervix carcinoma and papilloma, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Avastin and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include the cervix, cervix and testes, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : ¹² A female reproductive organ cancer that is located in the cervix.

CDC : ³ Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

UniProtKB/Swiss-Prot : ⁷⁵ Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : ⁶³ About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer.The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : ⁷⁶ Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Description from OMIM: 603956

Sources

Related Diseases for Cervical Cancer

Diseases in the Cervical Cancer family:

Cervical Benign Neoplasm

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)

#	Related Disease	Score	Top Affiliating Genes
1	cervix carcinoma	33.9	FGFR3 HOXA11-AS STAT3 TP53
2	papilloma	32.7	CCND1 FGFR3 PTEN TP53
3	squamous cell carcinoma	32.1	CCND1 FGFR3 H19 HOTAIR HRAS MALAT1
4	adenocarcinoma	32.0	CCND1 FGFR3 H19 HRAS PIK3CA PTEN
5	retinoblastoma	31.8	CCND1 HOTAIR MALAT1 MEG3 TP53
6	sarcoma	31.5	HOTAIR HRAS PIK3CA TP53
7	uterine carcinosarcoma	31.4	HRAS PIK3CA PTEN TP53
8	penile cancer	31.4	CCND1 HRAS TP53
9	oral cancer	31.3	CCND1 MIR21 TP53
10	small cell cancer of the lung	31.3	HOTAIR MALAT1 MIR21 PIK3CA PTEN TP53
11	peutz-jeghers syndrome	31.3	PTEN SMAD4 TP53
12	endometrial stromal sarcoma	31.1	CCND1 MALAT1 TP53
13	melanoma	31.1	GAS5 H19 HOTAIR MALAT1 MEG3 PTEN
14	ovarian cancer	30.8	CCND1 GAS5 H19 HOTAIR HOXA11-AS MALAT1
15	breast cancer	30.8	CCND1 GAS5 H19 HOTAIR HOXA11-AS HRAS
16	lung cancer susceptibility 3	30.7	CCND1 FGFR3 GAS5 H19 HOTAIR HRAS
17	gastric cancer	30.6	CCND1 GAS5 H19 HOTAIR HOXA11-AS MALAT1
18	prostate cancer	30.5	CCND1 GAS5 H19 HOTAIR HRAS MALAT1
19	bladder cancer	30.5	CCEPR CCND1 FGFR3 GAS5 H19 HOTAIR
20	esophageal cancer	30.5	CCND1 GAS5 H19 HOTAIR HOXA11-AS HRAS
21	lung cancer	30.4	CCND1 GAS5 H19 HOTAIR HOXA11-AS HRAS
22	colorectal cancer	30.3	CCND1 FGFR3 GAS5 H19 HOTAIR HOXA11-AS
23	hepatocellular carcinoma	30.1	CCEPR CCND1 GAS5 H19 HOTAIR HOXA11-AS
24	primitive neuroectodermal tumor of the cervix uteri	12.4
25	malignant germ cell tumor of the cervix uteri	12.3
26	bladder squamous cell carcinoma	11.6	FGFR3 PIK3CA PTEN TP53
27	synchronous bilateral breast carcinoma	11.5	CCND1 PTEN TP53
28	ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3	11.5	PIK3CA PTEN TP53
29	renal cell carcinoma, papillary, 1	11.5	FGFR3 HRAS PIK3CA PTEN TP53
30	glioblastoma multiforme	11.5	CCND1 MIR21 PIK3CA PTEN STAT3 TP53
31	ovarian clear cell carcinoma	11.5	PIK3CA PTEN TP53
32	giant cell glioblastoma	11.5	FGFR3 PTEN TP53
33	female reproductive organ cancer	11.5	CCND1 HRAS PIK3CA PTEN TP53
34	adenoid cystic carcinoma	11.5	CCND1 HRAS PIK3CA PTEN TP53
35	ethmoid sinus cancer	11.5	CCND1 HRAS PIK3CA
36	nevus, epidermal	11.5	FGFR3 HRAS PIK3CA
37	ethmoid sinus adenocarcinoma	11.5	CCND1 HRAS PIK3CA
38	esophagus adenocarcinoma	11.5	MIR21 PIK3CA SMAD4 TP53
39	transitional cell carcinoma	11.5	FGFR3 HRAS PTEN TP53
40	prostate squamous cell carcinoma	11.5	HRAS PIK3CA TP53
41	adenosquamous cell lung carcinoma	11.5	FGFR3 HRAS PIK3CA
42	estrogen-receptor positive breast cancer	11.5	CCND1 PIK3CA TP53
43	anaplastic thyroid cancer	11.5	PIK3CA PTEN TP53
44	pilocytic astrocytoma	11.5	HRAS PIK3CA PTEN TP53
45	cell type cancer	11.5	CCND1 HRAS PTEN TP53
46	skin melanoma	11.5	HRAS PIK3CA PTEN TP53
47	brain cancer	11.5	HRAS PIK3CA PTEN STAT3 TP53
48	skin squamous cell carcinoma	11.5	HRAS PIK3CA TP53
49	thyroid hurthle cell adenoma	11.5	PIK3CA PTEN
50	rare adenocarcinoma of the breast	11.5	PIK3CA TP53

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Hydronephrosis	Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:

Sources

Symptoms & Phenotypes for Cervical Cancer

Clinical features from OMIM:

603956

Human phenotypes related to Cervical Cancer:

³²

#	Description	HPO Frequency	HPO Source Accession
1	neoplasm ³²		HP:0002664
2	abnormality of the cervical spine ³²		HP:0003319

UMLS symptoms related to Cervical Cancer:

pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased sensitivity to paclitaxel	GR00112-A-0	8.62	PTEN SMAD4

MGI Mouse Phenotypes related to Cervical Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.7	PTEN SMAD4 STAT3 TP53 CCND1 FGFR3
2	integument	MP:0010771	9.56	SMAD4 STAT3 TP53 CCND1 FGFR3 HRAS
3	neoplasm	MP:0002006	9.23	SMAD4 STAT3 TP53 CCND1 FGFR3 HRAS

Sources

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: ⁶³

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization) might be enough. If the tumor has already spread to the surrounding tissue, doctors usually recommend having surgery to remove the entire womb (a hysterectomy). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy.

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Avastin ¹⁸ ⁴⁹	BEVACIZUMAB	Genentech	July 2009
FDA Label: Avastin Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer Indications and Usage: ¹⁸ Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1) DrugBank Targets: ¹⁶ 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁸ Target: VEGF Action: inhibitor FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
2	Cervarix ¹⁸ ⁴⁹	Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant	GlaxoSmithKline	October 2009
FDA Label: Cervarix Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18 Indications and Usage: ¹⁸ DrugBank Targets: - Mechanism of Action: ¹⁸ Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins Action: activates/ provokes production FDA: -
3	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 471)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

84093 441203 2767

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

437-38-7

3345

Ritonavir

Approved, Investigational

Phase 4,Phase 3,Phase 2

155213-67-5

392622

Diazepam

Approved, Illicit, Investigational, Vet_approved

Phase 4

439-14-5

3016

Meperidine

Approved

Phase 4

57-42-1

4058

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 2

51-61-6, 62-31-7

681

Nicotine

Approved

Phase 4,Phase 1,Phase 2,Not Applicable

54-11-5

942 89594

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Nevirapine

Approved

Phase 4

129618-40-2

4463

Aluminum hydroxide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

21645-51-2

Iron

Approved

Phase 4,Phase 1,Phase 2

7439-89-6

23925

Bethanechol

Approved

Phase 4

674-38-4

2370

Peppermint

Approved, Nutraceutical

Phase 4

Vitamin C

Approved, Nutraceutical

Phase 4,Phase 2

50-81-7

5785 54670067

Vaccines

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Epoetin alfa

Phase 4,Phase 3

113427-24-0

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Adjuvants, Anesthesia

Phase 4,Phase 3,Not Applicable

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Analgesics, Opioid

Phase 4,Phase 3,Not Applicable

Anesthetics

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Anesthetics, General

Phase 4,Phase 3,Not Applicable

Anesthetics, Intravenous

Phase 4,Phase 3,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Narcotics

Phase 4,Phase 3,Not Applicable,Early Phase 1

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hypoglycemic Agents

Phase 4,Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 3,Phase 2

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Psychotropic Drugs

Phase 4,Phase 3,Phase 2

Anti-HIV Agents

Phase 4,Phase 3,Phase 2,Phase 1

Anti-Retroviral Agents

Phase 4,Phase 3,Phase 2,Phase 1

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1

Cytochrome P-450 CYP3A Inhibitors

Phase 4,Phase 3,Phase 2

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

protease inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Antibodies

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Immunoglobulins

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Fluorodeoxyglucose F18

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Disinfectants

Phase 4

Pharmaceutical Solutions

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Polyhexamethylene biguanide

Phase 4

Antidepressive Agents

Phase 4,Phase 2

Antidepressive Agents, Second-Generation

Phase 4,Phase 2

Cytochrome P-450 CYP2D6 Inhibitors

Phase 4,Phase 2

Dopamine Agents

Phase 4,Phase 2

Dopamine Uptake Inhibitors

Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 1301)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparing Health Services Interventions for the Prevention of HPV-related Cancer	Unknown status	NCT02837926	Phase 4
2	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	Unknown status	NCT01021904	Phase 4
3	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?	Unknown status	NCT01101750	Phase 4
4	Can Alternative Treatment Have an Impact on Cervical Dysplasia?	Unknown status	NCT00842738	Phase 4
5	Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies	Unknown status	NCT01835119	Phase 4	gum
6	Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer	Completed	NCT01988376	Phase 4
7	Effect of HPV Vaccination on Women Aged 25 Years	Completed	NCT02296255	Phase 4
8	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer	Completed	NCT00046969	Phase 4	cisplatin
9	Patient Navigation in the Safety Net:CONNECTeDD	Completed	NCT00613275	Phase 4
10	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)	Completed	NCT01544478	Phase 4
11	Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls	Completed	NCT01173900	Phase 4
12	Alternate Dosing Schedules Study for HPV Vaccine	Completed	NCT00862810	Phase 4
13	Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects	Completed	NCT00947115	Phase 4
14	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls	Completed	NCT00956553	Phase 4
15	Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy	Completed	NCT02684942	Phase 4	Meperidine;Fentanyl
16	Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents	Completed	NCT00534638	Phase 4
17	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease	Completed	NCT00815282	Phase 4
18	Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection	Completed	NCT01571141	Phase 4
19	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
20	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
21	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Completed	NCT03384511	Phase 4	Apatinib
22	Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)	Completed	NCT00552240	Phase 4	tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
23	Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines	Recruiting	NCT03180034	Phase 4
24	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study	Recruiting	NCT01824537	Phase 4
25	CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）	Active, not recruiting	NCT01895517	Phase 4
26	The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)	Active, not recruiting	NCT02629510	Phase 4	Tachosil
27	FASTER-Tlalpan Study	Active, not recruiting	NCT03105856	Phase 4
28	Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India	Active, not recruiting	NCT00923702	Phase 4
29	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.	Active, not recruiting	NCT01953107	Phase 4
30	Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females	Active, not recruiting	NCT01031069	Phase 4
31	Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients	Active, not recruiting	NCT02624349	Phase 4	Quadravalent human papillomavirus vaccine
32	To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer	Not yet recruiting	NCT03206684	Phase 4	PEG-rhG-CSF;rhG-CSF
33	Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA	Not yet recruiting	NCT02910596	Phase 4	bethanechol chloride
34	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.	Not yet recruiting	NCT03423082	Phase 4	18F fluciclovine
35	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.	Not yet recruiting	NCT03349463	Phase 4	Fluciclovine F18
36	Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities	Terminated	NCT00629993	Phase 4
37	A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.	Terminated	NCT00730847	Phase 4
38	Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis	Unknown status	NCT00846508	Phase 3	Cisplatin
39	Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer	Unknown status	NCT00548821	Phase 3	Cisplatin
40	Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients	Unknown status	NCT01756170	Phase 3	paclitaxel;cisplatin
41	Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer	Unknown status	NCT00842660	Phase 3	Gemzar (gemcitabine)
42	Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients	Unknown status	NCT01755845	Phase 3	paclitaxel;cisplatin
43	Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer	Unknown status	NCT01554397	Phase 2, Phase 3	Cisplatin
44	Usefulness of FDG-PET for Advanced Cervical Cancer	Unknown status	NCT00146458	Phase 3
45	Hydralazine Valproate for Cervical Cancer	Unknown status	NCT00532818	Phase 3	Hydralazine and magnesium valproate;Placebo
46	Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients	Unknown status	NCT01000415	Phase 3
47	Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma	Unknown status	NCT01405235	Phase 3	Paclitaxel;Cisplatin/Paclitaxel
48	IT-system Development for Reaching Cervix Cancer Screening Non-attenders	Unknown status	NCT02750124	Phase 2, Phase 3
49	Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome	Unknown status	NCT00348738	Phase 3	Erythropoietin
50	Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)	Unknown status	NCT01095198	Phase 2, Phase 3

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Sources

Genetic Tests for Cervical Cancer

Sources

Anatomical Context for Cervical Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

¹⁹

The Cervix

MalaCards organs/tissues related to Cervical Cancer:

⁴¹

Cervix, Testes, Lymph Node, Breast, Endothelial, T Cells, Uterus

Sources

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 4174)

#	Title	Authors	Year
1	Usefulness of the maximum standardized uptake value for the diagnosis and staging of patients with cervical cancer undergoing positron emission tomography/computed tomography. ( 29443749 )	Takagi H....Sasagawa T.	2018
2	Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study. ( 29446043 )	Okazawa-Sakai M....Takehara K.	2018
3	Long non-coding RNA HOTAIR and STAT3 synergistically regulate the cervical cancer cell migration and invasion. ( 29572071 )	Zhang Y....Jin Z.	2018
4	SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/I^-catenin signaling pathway via trans-suppressing I^-catenin in cervical cancer. ( 29970906 )	Li L....Liu X.F.	2018
5	Upregulation of Long Non-Coding RNA Small Nucleolar RNA Host Gene 12 Contributes to Cell Growth and Invasion in Cervical Cancer by Acting as a Sponge for MiR-424-5p. ( 29533945 )	Dong J....Xiao-Jin Z.	2018
6	ROS-Mediated Mitochondrial Pathway is Required for <i>Manilkara Zapota</i> (L.) P. Royen Leaf Methanol Extract Inducing Apoptosis in the Modulation of Caspase Activation and EGFR/NF-<i>I_</i>B Activities of HeLa Human Cervical Cancer Cells. ( 29977314 )	Tan B.L....Chan L.C.	2018
7	The dawn of novel STI prevention methods: modelling potential unintended effects of changes in cervical cancer screening guidelines on trichomoniasis. ( 29545472 )	RAPnn M.M....Turner K.M.	2018
8	Radiation-induced leiomyosarcoma of the rectum after cervical cancer treatment. ( 29439826 )	Garcia-Ortega D.Y....Cuellar-Hubbe M.	2018
9	Cervical cancer screening among transactional female sex workers in the Dominican Republic. ( 29966506 )	Richards S.D....Amesty S.	2018
10	Cervical cancer screening among Lebanese women. ( 29249573 )	Bou-Orm I.R....Adib S.M.	2018
11	Anti-Hu antibody-mediated limbic encephalitis associated with cervical cancer: A case report. ( 29607578 )	Shin K.J....Ji Y.I.	2018
12	Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk: A systematic review and meta-analysis. ( 29595663 )	Ding B....Shen Y.	2018
13	Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer. ( 29329882 )	Park S.H....Kim J.C.	2018
14	DNA methylation regulated microRNAs in human cervical cancer. ( 29077234 )	Varghese V.K....Satyamoorthy K.	2018
15	Prevalence and determinants in cytology testing for cervical cancer screening in Spain (2006-14). ( 29444273 )	Cobo-Cuenca A.I....Carmona-Torres J.M.	2018
16	Trichomonas vaginalis infection-associated risk of cervical cancer: A meta-analysis. ( 29980111 )	Yang S....Wu X.	2018
17	A case of peritoneal malignant mesothelioma following radiation therapy for cervical cancer. ( 29435293 )	Yano M....Yasuda M.	2018
18	Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. ( 29447263 )	Markt S.C....Wright A.A.	2018
19	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. ( 29444073 )	Hall M.T....Canfell K.	2018
20	AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer. ( 29126926 )	Bi L....Cheng X.	2018
21	Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. ( 29235108 )	Gultekin M....Sencan I.	2018
22	Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report. ( 29435291 )	Prasanna R....Khan M.A.	2018
23	Awareness and Beliefs About Cervical Cancer, the HPV Vaccine, and Cervical Cancer Screening Among Ghanaian Women with Diverse Education Levels. ( 29974412 )	Williams M.S....Fontaine K.	2018
24	Cervical Cancer HeLa Cell Autocrine Apoptosis Induced by Co-immobilized TNF-I+ plus IFN-I^ Biomaterials. ( 29436216 )	Li J....Guan Y.Q.	2018
25	The difficulties of secondary prophylaxis of cervical cancer in women suffering from paranoid schizophrenia - a case study. ( 29975365 )	Tylec A....Kucharska K.	2018
26	Adjuvant therapy after radical trachelectomy for stage I cervical cancer. ( 29977985 )	Hazell S.Z....Viswanathan A.N.	2018
27	Novel structural approaches concerning HPV proteins: Insight into targeted therapies for cervical cancer (Review). ( 29436691 )	Pappa K.I....Anagnou N.P.	2018
28	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetium-99m-nanocolloid. ( 29968916 )	Soergel P....Hertel H.	2018
29	Knowledge of cervical cancer and HPV vaccine in Bangladeshi women: a population based, cross-sectional study. ( 29325530 )	Islam J.Y....Nahar Q.	2018
30	Knowledge about cervical cancer and barriers toward cervical cancer screening among HIV-positive women attending public health centers in Addis Ababa city, Ethiopia. ( 29441700 )	Shiferaw S....Jemal A.	2018
31	Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-I_B Signaling Pathway. ( 29291370 )	Jin Y....Zheng J.	2018
32	Knowledge And Perception Of Female Nursing Students About Human Papilloma Virus (Hpv), Cervical Cancer And Attitudes Towards Hpv Vaccination. ( 29979917 )	DAPnmez S....ZeyneloA9lu S.	2018
33	The association of semaphorin 5A with lymph node metastasis and adverse prognosis in cervical cancer. ( 29977159 )	Xiao J.B....Liu H.D.	2018
34	Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. ( 29967343 )	Zhu H....Zhu X.	2018
35	Dual p16 and Ki-67 Expression in Liquid-Based Cervical Cytological Samples Compared to Pap Cytology Findings, Biopsies, and HPV Testing in Cervical Cancer Screening: A Diagnostic Accuracy Study. ( 29566392 )	Prigenzi K.C.K....Focchi G.R.A.	2018
36	<i>Bis</i>demethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells <i>via</i> Inhibition of NF-A,B, MMP-2 and -9 Pathways. ( 29970522 )	Liao C.L....Chung J.G.	2018
37	Investigating rectal toxicity associated dosimetric features with deformable accumulated rectal surface dose maps for cervical cancer radiotherapy. ( 29980214 )	Chen J....Zhen X.	2018
38	The distribution of human papillomavirus genotypes in cervical cancer and intraepithelial neoplasia lesions among Chinese women in Yunnan Province. ( 28697900 )	Yuanyue L....Xueshan X.	2018
39	Clinical outcomes with MRI-guided image-based brachytherapy in cervical cancer: An institutional experience. ( 29102740 )	Simha V....Ghoshal S.	2018
40	Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. ( 29436615 )	Tian R....Wang K.	2018
41	Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute. ( 29048733 )	Yang J....Ehsani L.	2018
42	Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65A years. ( 29124542 )	Silver M.I....Gravitt P.E.	2018
43	Imaging and staging of neuroendocrine cervical cancer. ( 29974177 )	Elsherif S....Bhosale P.	2018
44	A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. ( 29963597 )	Sachan P.L....Sachan R.	2018
45	Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells. ( 29978381 )	Ozfiliz-Kilbas P....Palavan-Unsal N.	2018
46	Uterine and cervical cancer with irreducible pelvic organ prolapse. ( 29852160 )	Chung C.P....Wakabayashi M.T.	2018
47	Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer. ( 29524410 )	Song Y....Hua K.	2018
48	MEHP promotes the proliferation of cervical cancer via GPER mediated activation of Akt. ( 29382535 )	Yang W....Li X.	2018
49	Prediction of outcome using pretreatment<sup>18</sup>F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. ( 29222685 )	Lucia F....Schick U.	2018
50	Therapeutic effects of I^-elemene via attenuation of the Wnt/I^-catenin signaling pathway in cervical cancer cells. ( 29363722 )	Wang L....Wu X.	2018

Sources

Genes for Cervical Cancer

Genes related to Cervical Cancer (8 elite genes):

(show top 50) (show all 114)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	1241.7	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Variants (show sections)	8589699 10471491 15772091 (more) 11114733 18794123 15105428
2	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	441.04	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18180098 16391859
3	PTEN	Phosphatase And Tensin Homolog	Protein Coding	437.78	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	PTEN::MIR21 ⁴⁷	MIR21 Macro RNA (hsa-miR-21) targets PTEN
4	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	436.67	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	TP53	Tumor Protein P53	Protein Coding	435.31	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1849234 1349102 16681751 (more) 14756543 10895031 12445252 17375700 11535556 15908516 11836622 16481734 12144822 10794489 14764039 12618167 8674566 1349102 20200430 8774641 10754463 8806692 15640620 9742979 19625214 15899386 18313527 16761419 15790450 14529662 12144687 17012841 17178878 10726657 8942499 1322252 11429213 9155557 16488468 17912468 11485021 11174479 7909855 10741285 10775508 10918193 12451999 17192686 17177838 12821336 12713987 16544983 16054204 15994823 14678586 12499281 10023783 8674061 16841142 18599197 11158620 11212257 10618709 9367711 7591279 8172533 20167600 19423538 15581977 15073118 12534455 11996107 10928171 11885807 8546000 7962045 8397367 19012699 16324714 15905603 15797321 15566643 8623835 8388491 16287099 15143339 12406566 10975290 10729761 9704765 9334921 8039779 11072671 10760422 7841033 1933850 17713095 17324262 15047208 14513722 11146234 15863130
6	SMAD4	SMAD Family Member 4	Protein Coding	413.61	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18425078 12894231 17997817 (more) 16269171 15531914 11745435
7	MIR21	MicroRNA 21 The inhibition of miR-21 in HeLa cervical cancer cells caused profound suppression of cell proliferation, and up-regulated the expression of the tumor suppressor gene PDCD4. We also provide direct evidence that PDCD4-3'UTR is a functional target of miR-21 and that the 18bp putative target site can function as the sole regulatory element in HeLa cells. These results suggest that miR-21 may play an oncogenic role in the cellular processes of cervical cancer and may serve as a target for effective therapies.	RNA Gene	407.4	Causal ⁴⁷ Unspecified ⁴⁷ GeneCards inferred via : Publications (show sections)	19682430 17616659
8	MIR214	MicroRNA 214 We determined the expression level of miR-214 and found it is downregulated in cervical cancer compared with normal tissue. Overexpression of miR-214 in HeLa cells, a human cervical cancer cell line, significantly inhibited cell proliferation according to the MTT and colony forming assays. HeLa cells that stably overexpress miR-214 downregulate the expression of MEK3 and JNK1 at both mRNA and protein levels. Further investigation revealed that miR-214 regulates the expression of MEK3 and JNK1 by targeting the 3'UTRs of these genes. Collectively, these results suggest that miR-214 negatively regulates HeLa cell proliferation by targeting the noncoding regions of MEK3 and JNK1 mRNAs.	RNA Gene	357.05	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19859982
9	TMPOP2	Thymopoietin Pseudogene 2 lncRNA-EBIC was upregulated in cervical cancer. lncRNA-EBIC was an oncogenic lncRNA,which could promote tumor cell invasion in CC by binding to EZH2 and inhibiting E-cadherin expression. Dysfunction Pattern: Regulation [up-regulated]	Pseudogene	165.15	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications Gene name (show sections)	25007342
10	CCND1	Cyclin D1 Generally,we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21,GAS5,MEG3,ANRIL,and ncRNA-CCND1) are up-regulated and some others (TUG1,UCA1,and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21,ncRNA-CCND1,and MEG3,a similar up-regulation pattern was obvious in both cell linewhere the increase was generally more pronounced in BLM-treated cells. Dysfunction Pattern: Regulation [up-regulated]	Protein Coding	163.68	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	22487937
11	HOTAIR	HOX Transcript Antisense RNA HOTAIR expression was elevated while miR-143-3p expression was reduced in cervical cancer tissues and cell lines. HOTAIR knockdown suppressed proliferation and enhanced apoptosis in cervical cancer cells. Moreover, HOTAIR could function as a sponge for miR-143-3p. The inhibitory effect of HOTAIR knockdown on cervical cancer cells growth was abolished following decrease of miR-143-3p expression. Furthermore, HOTAIR promoted BCL2 expression by modulating miR-143-3p. BCL2 overexpression attenuated the tumor-suppressive effect of miR-143-3p in cervical cancer. Finally, the carcinogenicity of HOTAIR was validated in mice. Dysfunction Pattern: Expression [high expression]	RNA Gene	162.61	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29336659
12	STAT3	Signal Transducer And Activator Of Transcription 3 Our results showed that expression of HOTAIR was significantly upregulated in cervical cancer cells and inhibition of the expression of HOTAIR in HeLa cervical cancer cells resulted in suppression of cell proliferation, migration and invasion. Further, analysis of the promoter of HOTAIR, revealed that STAT3 could potentially regulate the activity of the HOTAIR in cervical cancer cells and inhibition of STAT3 had similar effects on the proliferation, migration and invasion of the cervical cancer cells as that of HOTAIR. Further, the suppression of STAT3 expression was associated with concomitant downregulation of IncRNA HOTAIR as indicated by the qRT-PCR. To unveil if STAT3 and HOTAIR have synergistic effects on the cell migration and invasion, si-STAT3 and si-HOTAIR were co-transformed into cervical HeLa cancer cells and it was observed that STAT3 and HOTAIR could synergistically inhibit the proliferation, migration and invasion of the cervical cancer cells. Dysfunction Pattern: Regulation	Protein Coding	162.5	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29572071
13	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1 Human MALAT-1 long non-coding RNA is overexpressed in cervical cancer metastasis and promotes cell proliferation, invasion and migration. Dysfunction Pattern: Expression	RNA Gene	161.64	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	27658300
14	PVT1	Pvt1 Oncogene Our study found that PVT1 was upregulated in cervical cancer tissue and cell lines. After transfecting PVT1 siRNA, the proliferation, migration, and invasion of cervical cancer cells were markedly decreased. miRNA expression profiles demonstrate that miR-424 was markedly downregulated in cervical cancer tissue. Bioinformatics analysis revealed that miR-424 was potentially targeted by PVT1, which was confirmed by dual-luciferase reporter assay. Pearson's correlation analysis showed that PVT1 expression was negatively related to miR-424 expression in glioma cancer tissues. Finally, lowered expression of miR-424 could recover the tumor-suppressive effects of PVT1 knockdown in cervical cancer cell lines. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	161	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28276314
15	CCEPR	Cervical Carcinoma Expressed PCNA Regulatory LncRNA The cervical carcinoma expressed PCNA regulatory (CCEPR) lncRNA is highly expressed in cervical cancers and expression correlates with tumor size and patient outcome. We report that CCEPR is a nuclear lncRNA and that HPV16 E6 oncogene expression causes increased CCEPR expression through a mechanism that is not directly dependent on TP53 inactivation. CCEPR depletion in cervical carcinoma cell lines reduces viability, while overexpression enhances viability. Dysfunction Pattern: Expression [high expression]	RNA Gene	160.96	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29427865
16	GAS5	Growth Arrest Specific 5 Our results indicate that GAS5 is a direct target of miR-21 and can predict the clinical staging of cervical cancer. Dysfunction Pattern: Interaction [miR-21]	RNA Gene	160.31	Experimental evidence: Interaction ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28671039
17	HOXA11-AS	HOXA11 Antisense RNA The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. Dysfunction Pattern: Regulation	RNA Gene	159.69	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	27792998
18	H19	H19, Imprinted Maternally Expressed Transcript High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Dysfunction Pattern: Mutation	RNA Gene	158.19	Experimental evidence: Mutation ³⁹ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8570220 8570220
19	MEG3	Maternally Expressed 3 The results indicated that 7 lncRNAs were upregulated and 4 lncRNAs were downregulated in CC patients. The fold?changes between the RT?qPCR experiments and the TCGA bioinformatics analyses were the same. Furthermore, the area under the receiver operating characteristic (ROC) curve of four lncRNAs (EMX20S, MEG3, SYS1?DBNDD2 and MIR9?3HG) indicated that their combined use may have a significant diagnostic value in CC (P<0.05). Dysfunction Pattern: Regulation	RNA Gene	156.5	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	29620291
20	TUG1	Taurine Up-Regulated 1 TUG1 was found to be significantly upregulated in cervical cancer tissues and four cervical cancer cell lines by quantitative real-time polymerase chain reaction (qRT-PCR). Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	156.5	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	29029428
21	CDKN2B-AS1	CDKN2B Antisense RNA 1 In present study, RT-PCR showed that ANRIL expression was significantly up-regulated in cervical cancer tumors and cell lines. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	156.5	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	28550682
22	CCAT1	Colon Cancer Associated Transcript 1 The results demonstrated that lncRNA CCAT1 was highly expressed in the cervical cancer tissue compared with the adjacent normal tissue. High expression of lncRNA CCAT1 was positively associated with tumor size, and there was correlation between high lncRNA CCAT1 expression and a poor survival rate of cervical cancer. The cell viability, and migratory and invasive abilities were suppressed by silencing CCAT1. Dysfunction Pattern: Expression [high expression]	RNA Gene	156.5	Experimental evidence: Expression ³⁹ GeneCards inferred via : Publications (show sections)	28849215
23	CRNDE	Colorectal Neoplasia Differentially Expressed The expressions of CRNDE in cervical cancer tissues and cells were higher than those in normal tissues and cells. CCK-8 assay and clone formation assay showed that the knockdown of CRNDE could inhibit the cell proliferation of HeLa and C-33A cells. Wound healing assay indicated that the downregulation of CRNDE expression could suppress the cell migration. The result of a Transwell assay demonstrated that the number of invasion cells reduced in the CRNDE-si group in comparison with the Mock group. Dysfunction Pattern: Expression [high expression]	Protein Coding	156.15	Experimental evidence: Expression ³⁹ GeneCards inferred via : Publications (show sections)	29194035
24	CCAT2	Colon Cancer Associated Transcript 2 CCK8 assay showed that CCAT2 knockdown inhibited cell proliferation in HeLa,CaSki,and SiHa cells. The flow cytometry confirmed the results that knockdown of CCAT2 could induce cervical cancer cells cycle G1 phase arrestment and trigger the cells apoptosis Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	156.15	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	26983975
25	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA The expression of HULC was upregulated in cervical cancer, and associated with overall survival, indicating that HULC may serve as a predictive biomarker for the prognosis of cervical cancer. Dysfunction Pattern: Expression	RNA Gene	156.15	Experimental evidence: Expression ³⁹ GeneCards inferred via : Publications (show sections)	27775802
26	TUSC8	Tumor Suppressor Candidate 8 The results showed that XLOC_010588 expression in cervical cancer was significantly downregulated. Decreased XLOC_010588 expression was correlated with FIGO stage,tumor size and SCC-Ag. Moreover,cervical cancer patients with XLOC_010588 lower expression have shown poorer prognosis. Western blot assays confirmed that XLOC_010588 physically associates with c-Myc,consequently decreasing the expression of c-Myc. The expression of XLOC_010588 and c-Myc is strongly correlated in cervical cancer tissues. Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	154.65	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	24667250
27	LOC100131868	Serine/Threonine-Protein Phosphatase 4 Regulatory Subunit 2-Like MIR100HG and AC024560.2 may be a potential biomarkers of PLNM and these lncRNAs may provide broader perspective for combating cervical cancer metastasis. Dysfunction Pattern: Expression	Pseudogene	154.44	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	27035672
28	LINC01101	Long Intergenic Non-Protein Coding RNA 1101 After analysing the microarray results, we identified 15,387 RNA species differentially expressed in E7-siRNA-transfected cells compared with controls (fold change >2). The expression profiles of lncRNA species highlighted 731 lncRNAs and 203 lincRNAs. We selected two lincRNAs (LINC01101 and LINC00277) and we evaluated the expression profile in HPV-induced neoplasia. Both lincRNAs investigated display a significantly reduced pattern of expression in cervical lesions and cancer, associated with clinical parameters. A connection between HPV presence and lincRNAs was noted. hrHPV-positive samples exhibit significantly reduced LINC01101 and LINC00277 expression level (P < 0.05). Dysfunction Pattern: Expression [high expression]	RNA Gene	154.39	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	28767188
29	MIR9-3HG	MIR9-3 Host Gene The results indicated that 7 lncRNAs were upregulated and 4 lncRNAs were downregulated in CC patients. The fold?changes between the RT?qPCR experiments and the TCGA bioinformatics analyses were the same. Furthermore, the area under the receiver operating characteristic (ROC) curve of four lncRNAs (EMX20S, MEG3, SYS1?DBNDD2 and MIR9?3HG) indicated that their combined use may have a significant diagnostic value in CC (P<0.05). Dysfunction Pattern: Regulation	RNA Gene	154.39	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	29620291
30	BLACAT1	Bladder Cancer Associated Transcript 1 It was demonstrated that BLACAT1 was highly expressed in human cervical cancer tissues and cell lines. The knockdown of BLACAT1 with specific short hairpin RNA reduced colony formation rates in ME180 and C33A cells. Cell cycle and cell proliferation assays revealed that depletion of BLACAT1 in ME180, and C33A cells arrested the cell cycle at the G0/G1 phase and inhibited cell proliferation. Transwell assays demonstrated that the knockdown of BLACAT1 inhibited cell migration and invasion in ME180, and C33A cells. Moreover, wound-healing assays supported the aformentioned observations. Western blot analysis showed that the knockdown of BLACAT1 in ME180 and C33A cells decreased the protein levels of cyclin B1, cell division cycle 25C, and N-cadherin, while increasing the protein level of E-cadherin. Dysfunction Pattern: Expression [high expression]	RNA Gene	153.92	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	29456724
31	PAX8-AS1	PAX8 Antisense RNA 1 Expression quantitative trait loci in long non-coding RNA PAX8-AS1 are associated with decreased risk of cervical cancer. Dysfunction Pattern: Expression	RNA Gene	153.8	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	27225188
32	EWSAT1	Ewing Sarcoma Associated Transcript 1 After analysing the microarray results, we identified 15,387 RNA species differentially expressed in E7-siRNA-transfected cells compared with controls (fold change >2). The expression profiles of lncRNA species highlighted 731 lncRNAs and 203 lincRNAs. We selected two lincRNAs (LINC01101 and LINC00277) and we evaluated the expression profile in HPV-induced neoplasia. Both lincRNAs investigated display a significantly reduced pattern of expression in cervical lesions and cancer, associated with clinical parameters. A connection between HPV presence and lincRNAs was noted. hrHPV-positive samples exhibit significantly reduced LINC01101 and LINC00277 expression level (P < 0.05). Dysfunction Pattern: Expression [high expression]	RNA Gene	153.45	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	28767188
33	SNHG16	Small Nucleolar RNA Host Gene 16 By employing the bioinformatics analysis tools, we revealed that miR-216-5p could interact with SNHG16 and there existed a negative correlation between the expression levels of miR-216-5p and SNHG16 in cervical cancer specimens. Furthermore, RIP assay, RNA pulldown system and dual luciferase reporter assays confirmed that SNHG16 directly targeted miR-216-5p by harboring the binding sites of microRNA in the SNHG16 sequence. Additionally, bioinformatics analysis provided an evidence that ZEB1 was a potential target of miR-216-5p. Dysfunction Pattern: Interaction [miR-216-5p/ZEB]	RNA Gene	153.37	Experimental evidence: Interaction ³⁹ DISEASES inferred ¹⁵	29126969
34	ZNRD1ASP	Zinc Ribbon Domain Containing 1 Antisense, Pseudogene Expression quantitative trait loci in long non-coding RNA ZNRD1-AS1 influence cervical cancer development. Dysfunction Pattern: Expression	Pseudogene	153.36	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	26328261
35	MIR100HG	Mir-100-Let-7a-2-Mir-125b-1 Cluster Host Gene MIR100HG and AC024560.2 may be a potential biomarkers of PLNM and these lncRNAs may provide broader perspective for combating cervical cancer metastasis. Dysfunction Pattern: Expression	RNA Gene	153.35	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	27035672
36	NNT-AS1	NNT Antisense RNA 1 Our results showed that NNT-AS1 expression in cervical cancer tissues compared with adjacent non-tumor tissues the overexpression of NNT-AS1 was positively associated with advanced FIGO stage, lymph node metastasis, depth of cervical invasion and poorer overall survival. Dysfunction Pattern: Expression [overexpression]	RNA Gene	153.35	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	28628975
37	SPRY4-IT1	SPRY4 Intronic Transcript 1 LncRNA SPRY4-IT1 may be a novel molecule involved in cervical cancer progression, which may be of use as both a potential predictor and therapeutic target. Dysfunction Pattern: Regulation	RNA Gene	153.17	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	27642559
38	NEAT1	Nuclear Paraspeckle Assembly Transcript 1 Reverse transcription?quantitative polymerase chain reaction results demonstrated that the expression of NEAT1 was higher in cervical cancer cells/tissues compared with that in normal human keratinocytes/tissues. Patients with higher NEAT1 level had poorer clinical characteristics and a shorter survival time compared with those that exhibited lower NEAT1 expression levels. In vitro, flow cytometery analysis revealed that transfection with NEAT1 small interfering RNA retarded cervical cancer cell (Caski and HeLa) growth by decreasing the percentage of S phase in the cell cycle and inducing cell apoptosis. In addition, the colony formation assay, wound healing assay and matrigel invasion assay results indicated that downregulation of NEAT1 inhibited colony formation, cell migration and invasion. Further investigation using the luciferase reporter assay revealed that the expression of mircoRNA?101 (miR?101) target gene Fos was positively associated with NEAT1 expression due to NEAT1?competitive molecular sequestering of miR?101 via base pairing. Furthermore, reduction of miR?101 expression by inhibitor transfection reversed the effect of NEAT1 siRNA on cervical cancer cells. Dysfunction Pattern: Expression [high expression]	RNA Gene	153.15	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	29207151
39	SNHG12	Small Nucleolar RNA Host Gene 12 SNHG12 was found to be abnormally elevated in human cervical cancer tissues compared with paired adjacent normal tissues. Moreover, high SNHG12 expression in tumor tissues was significantly correlated with vascular involvement, lymph node metastasis, advanced FIGO stage and poor prognosis. Furthermore, the knockdown of SNHG12 was found to inhibit proliferation, migration and invasion of cervical cancer cells in vitro, and silencing SNHG12 was shown to suppress tumor growth in a nude mouse model. Mechanistic studies showed that SNHG12 functioned as an endogenous sponge for miR-424-5p, thereby downregulating the expression of miR-424-5p in cervical cancer. Furthermore, the inhibition of miR-424-5p in SNHG12-depleted cells partially reversed the effects on cervical cancer cell apoptosis, adhesion and invasion. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	153.13	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	29533945
40	NPTN-IT1	NPTN Intronic Transcript 1 The results showed that lncRNA LET expression in cervical cancer tissues was significantly down-regulated compared with the adjacent non-tumor tissues (P < 0.05). Decreased lncRNA LET expression was significantly correlated with FIGO stage,lymph node metastasis,and depth of cervical invasion (P < 0.05),but not other clinical characteristics. Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	153.06	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	25755778
41	HAGLR	HOXD Antisense Growth-Associated Long Non-Coding RNA The results indicated that HOXD-AS1 was upregulated in cervical cancer cells significantly. Meanwhile, HOXD-AS1 expression was involved in tumor-node-metastasis stages, lymphovascular invasion, lymph node metastasis, as well as recurrence. HOXD-AS1 knockdown remarkably suppressed cervical cancer cell proliferation, colony formation capacity, and the Ras/ERK signaling pathway in vitro. Furthermore, xenograft assays confirmed the results in vivo. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	29228418
42	RNY3	RNA, Ro-Associated Y3 On average,all four hY RNAs are significantly overexpressed in solid tumours between 4- and 13-fold,compared to the corresponding normal tissues. In particular,hY1 and hY3 RNAs are overexpressed in carcinomas (and adenocarcinomas) of the bladder,cervix,colon,kidney,lung and prostate with extremely high statistical significance (ANOVA,between groups,P<10e-22). Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	18283318
43	BCAR4	Breast Cancer Anti-Estrogen Resistance 4 Novel recurrent focal amplification events were identified (in genomic order) at 7p11.2 (EGFR; 17%), 9p24.1 (CD274, PDCD1LG2; 21%), 13q22.1 (KLF5; 18%), and 16p13.13 (BCAR4; 20%). Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	28112728
44	LINP1	LncRNA In Non-Homologous End Joining Pathway 1 We found that LINP1 associates with NHEJ proteins (Ku80 and DNA-PKcs). LINP1 translocates from cytosol to nucleus in response to irradiation. In addition, LINP1 knockdown significantly increases the levels of cleaved caspase3 and PARP, leading to enhanced cell apoptosis after ionizing radiation (IR). LINP1-knockdown cells showed delayed repairs of DNA double-strand breaks (DSBs) after IR. Finally, LINP1 knockdown increases radiosensitivity of Hela S3 cells. Dysfunction Pattern: Interaction [NHEJ pathway]	RNA Gene	150	Experimental evidence: Interaction ³⁹	29527968
45	LOC105372429	Uncharacterized LOC105372429 The variant genotype of AC008392.1 SNP rs7248320 was significantly associated with increased risk of HCC and cervical cancer. Moreover,the effect of rs7248320 on cervical cancer risk was more prominent in premenopausal women. Further interactive analysis detected a significantly multiplicative interaction between rs7248320 and menopausal status on cervical cancer risk. Dysfunction Pattern:	RNA Gene	150	Experimental evidence ³⁹	26147888
46	HTATIP2	HIV-1 Tat Interactive Protein 2 Overexpression of lnc-CC3 promoted migration and invasion by SiHa cervical cancer cells in vitro and in vivo,increased Slug expression,and reduced the expression of the epithelial cell marker E-cadherin. Conversely,lnc-CC3 knockdown altered SiHa cell morphology and increased the expression of E-cadherin,thereby suppressing migration and invasion. Dysfunction Pattern: Regulation [up-regulated]	Protein Coding	150	Experimental evidence: Regulation ³⁹	27223436
47	PCAT1	Prostate Cancer Associated Transcript 1 The results of CCK-8, clonogenic and wound-healing assay showed that the decreased expression of lncRNA PCAT-1 attenuated the proliferation and metastasis of cells. The results of matrigel cell invasion assay manifested that the decreased expression of lncRNA PCAT-1 could reduce the invasion ability. The up-regulation of lncRNA PCAT-1 was associated with poor prognosis of patients with cervical cancer. Dysfunction Pattern: Regulation	RNA Gene	150	Experimental evidence: Regulation ³⁹	29687842
48	RSU1P2	Ras Suppressor Protein 1 Pseudogene 2 LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Dysfunction Pattern: Regulation	Pseudogene	150	Experimental evidence: Regulation ³⁹	27487126
49	PANDAR	Promoter Of CDKN1A Antisense DNA Damage Activated RNA The results of qRT-PCR showed that the expression level of PANDAR was significantly up-regulated in cervical cancer tissues compared with that in cancer-adjacent tissues. Statistical analysis showed that PANDAR expression was correlated with International Federation of Gynecology and Obstetrics (FIGO) staging, tumor size and tumor invasion degree. Kaplan-Meier survival analysis showed that the survival time of patients with highly expressed PANDAR was shorter than that of patients with lowly expressed PANDAR. Cox multivariate regression analysis showed that PANDAR could be used as an independent prognostic factor for patients with cervical cancer. CCK-8 results showed that interference in PANDAR significantly inhibited tumor cell proliferation. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	29131264
50	APBB3	Amyloid Beta Precursor Protein Binding Family B Member 3 To verify the role of lncRNA SRA in cell proliferation, migration, and invasion, lncRNA RNA interference was utilized to knock down lncRNA SRA expression in cervical cancer cell lines, resulting in our discovery that lncRNA SRA knockdown inhibited cell proliferation, cell migration and tumor invasion in the cervical cancer cell lines. Additionally, in vitro experiments using the lncRNA SRA-knockdown cervical cancer cell lines revealed that lncRNA SRA is a strong inducer and modulator of the expression of genes related to epithelial-mesenchymal transition and the NOTCH signaling pathway. In conclusion, our findings demonstrated that lncRNA SRA is highly correlated with cancer progression and cervical cancer cell proliferation and migration. Dysfunction Pattern: Regulation	Protein Coding	150	Experimental evidence: Regulation ³⁹	29039612

Sources

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

⁷⁵

#	Symbol	AA change	Variation ID	SNP ID
1	FGFR3	p.Ser249Cys	VAR_004149	rs121913483

ClinVar genetic disease variations for Cervical Cancer:

⁶

(show top 50) (show all 262)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	PTEN	NM_000314.6(PTEN): c.389G> A (p.Arg130Gln)	single nucleotide variant	Pathogenic	rs121909229	GRCh37	Chromosome 10, 89692905: 89692905
2	PTEN	NM_000314.6(PTEN): c.389G> A (p.Arg130Gln)	single nucleotide variant	Pathogenic	rs121909229	GRCh38	Chromosome 10, 87933148: 87933148
3	SMAD4	NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys)	single nucleotide variant	Pathogenic	rs80338963	GRCh37	Chromosome 18, 48591918: 48591918
4	SMAD4	NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys)	single nucleotide variant	Pathogenic	rs80338963	GRCh38	Chromosome 18, 51065548: 51065548
5	HRAS	NM_005343.3(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
6	HRAS	NM_005343.3(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
7	HRAS	NM_005343.3(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh37	Chromosome 11, 534288: 534288
8	HRAS	NM_005343.3(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh38	Chromosome 11, 534288: 534288
9	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh38	Chromosome 11, 533467: 533467
10	HRAS	NM_005343.3(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh37	Chromosome 11, 534286: 534286
11	HRAS	NM_005343.3(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh38	Chromosome 11, 534286: 534286
12	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh37	Chromosome 11, 533467: 533467
13	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh37	Chromosome 11, 533466: 533466
14	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh38	Chromosome 11, 533466: 533466
15	HRAS	NM_005343.3(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
16	HRAS	NM_005343.3(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
17	PIK3CA	NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)	single nucleotide variant	Pathogenic	rs121913279	GRCh37	Chromosome 3, 178952085: 178952085
18	PIK3CA	NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)	single nucleotide variant	Pathogenic	rs121913279	GRCh38	Chromosome 3, 179234297: 179234297
19	PIK3CA	NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu)	single nucleotide variant	Pathogenic	rs121913279	GRCh37	Chromosome 3, 178952085: 178952085
20	PIK3CA	NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu)	single nucleotide variant	Pathogenic	rs121913279	GRCh38	Chromosome 3, 179234297: 179234297
21	PIK3CA	NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh37	Chromosome 3, 178936094: 178936094
22	PIK3CA	NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh38	Chromosome 3, 179218306: 179218306
23	PIK3CA	NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913274	GRCh38	Chromosome 3, 179218304: 179218304
24	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	GRCh37	Chromosome 3, 178936091: 178936091
25	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	GRCh38	Chromosome 3, 179218303: 179218303
26	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	NCBI36	Chromosome 3, 180418785: 180418785
27	PIK3CA	NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913274	GRCh37	Chromosome 3, 178936092: 178936092
28	PIK3CA	NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh37	Chromosome 3, 178936094: 178936094
29	PIK3CA	NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh38	Chromosome 3, 179218306: 179218306
30	PIK3CA	NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)	single nucleotide variant	Pathogenic	rs121913274	GRCh37	Chromosome 3, 178936092: 178936092
31	PIK3CA	NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)	single nucleotide variant	Pathogenic	rs121913274	GRCh38	Chromosome 3, 179218304: 179218304
32	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh37	Chromosome 14, 105246551: 105246551
33	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh38	Chromosome 14, 104780214: 104780214
34	GNAS	NM_000516.5(GNAS): c.601C> T (p.Arg201Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11554273	GRCh37	Chromosome 20, 57484420: 57484420
35	GNAS	NM_000516.5(GNAS): c.601C> T (p.Arg201Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11554273	GRCh38	Chromosome 20, 58909365: 58909365
36	GNAS	NM_000516.5(GNAS): c.602G> A (p.Arg201His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913495	GRCh37	Chromosome 20, 57484421: 57484421
37	GNAS	NM_000516.5(GNAS): c.602G> A (p.Arg201His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913495	GRCh38	Chromosome 20, 58909366: 58909366
38	FGFR3	NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)	single nucleotide variant	Pathogenic	rs121913483	GRCh37	Chromosome 4, 1803568: 1803568
39	FGFR3	NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)	single nucleotide variant	Pathogenic	rs121913483	GRCh38	Chromosome 4, 1801841: 1801841
40	CTNNB1	NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913396	GRCh37	Chromosome 3, 41266098: 41266098
41	CTNNB1	NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913396	GRCh38	Chromosome 3, 41224607: 41224607
42	CTNNB1	NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913403	GRCh37	Chromosome 3, 41266113: 41266113
43	CTNNB1	NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913403	GRCh38	Chromosome 3, 41224622: 41224622
44	CTNNB1	NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28931588	GRCh37	Chromosome 3, 41266097: 41266097
45	CTNNB1	NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28931588	GRCh38	Chromosome 3, 41224606: 41224606
46	CTNNB1	NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913403	GRCh37	Chromosome 3, 41266113: 41266113
47	CTNNB1	NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913403	GRCh38	Chromosome 3, 41224622: 41224622
48	SMAD4	NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly)	single nucleotide variant	Likely pathogenic	rs80338963	GRCh37	Chromosome 18, 48591918: 48591918
49	SMAD4	NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly)	single nucleotide variant	Likely pathogenic	rs80338963	GRCh38	Chromosome 18, 51065548: 51065548
50	SMAD4	NM_005359.5(SMAD4): c.1082G> A (p.Arg361His)	single nucleotide variant	Pathogenic	rs377767347	GRCh37	Chromosome 18, 48591919: 48591919

Copy number variations for Cervical Cancer from CNVD:

⁷ (show top 50) (show all 142)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13747	1	1	27800000	Gain	EPHB2	Cervical cancer
2	16425	1	124300000	247249719	Arm		Cervical cancer
3	30310	1	241700000	247249719	Gain		Cervical cancer
4	31746	1	30500000	163800000	Gain	AIM2	Cervical cancer
5	32175	1	34400000	39600000	Gain	CDCA8	Cervical cancer
6	47124	10	89600000	98000000	Loss	PTEN	Cervical cancer
7	48645	11	101600000	102400000	Amplification	MMP1	Cervical cancer
8	48646	11	101600000	102400000	Amplification	MMP13	Cervical cancer
9	51761	11	130300000	134452384	Loss		Cervical cancer
10	51791	11	130800000	135006516	Loss	HNT	Cervical cancer
11	51792	11	130800000	135006516	Loss	OPCML	Cervical cancer
12	55435	11	52900000	134452384	Loss		Cervical cancer
13	57095	11	63100000	130300000	Loss	INT2	Cervical cancer
14	57096	11	63100000	130300000	Loss	MEN1	Cervical cancer
15	57097	6	99389300	99393387	Loss	POUF3	Cervical cancer
16	57098	11	63100000	130300000	Loss	TRIM29	Cervical cancer
17	59362	11	74700000	85300000	Gain		Cervical cancer
18	77051	13	39500000	52200000	Loss	RB	Cervical cancer
19	81044	14	100400000	106368585	Gain	AKT1	Cervical cancer
20	97280	16	1	40700000	Loss		Cervical cancer
21	106741	17	1	11200000	Loss	TP53	Cervical cancer
22	108734	17	22200000	28800000	Loss	CCL2	Cervical cancer
23	109725	17	28500000	29700000	Amplification		Cervical cancer
24	109738	17	28800000	35400000	Amplification	ERBB2	Cervical cancer
25	111034	17	34900000	35300000	Amplification		Cervical cancer
26	111283	17	35400000	54900000	Amplification	ABCC3	Cervical cancer
27	112092	17	37856253	37884915	Amplification	ERBB2	Cervical cancer
28	112304	17	38544772	38574202	Amplification	TOP2A	Cervical cancer
29	117589	17	72900000	78774742	Gain		Cervical cancer
30	124103	19	1	30200000	Gain		Cervical cancer
31	124104	19	1	30200000	Loss		Cervical cancer
32	124177	19	1	6900000	Gain	SMARCA4	Cervical cancer
33	124219	19	1	6900000	Gain		Cervical cancer
34	124597	19	1156797	1179434	Deletion	LKB1	Cervical Cancer
35	124598	19	1156797	1179434	Deletion	LKB1	Cervical cancer
36	130163	19	47800000	57600000	Gain	LIG1	Cervical cancer
37	134165	19	9500000	14500000	Gain		Cervical cancer
38	140388	2	197100000	242951149	Loss	CASP10	Cervical cancer
39	140389	2	197100000	242951149	Loss	CFLAR	Cervical cancer
40	140390	2	197100000	242951149	Loss	PPP1R7	Cervical cancer
41	151917	20	27100000	28400000	Amplification	AHCY	Cervical cancer
42	151918	20	27100000	28400000	Amplification	ASXL1	Cervical cancer
43	151919	20	27100000	28400000	Amplification	C20orf20	Cervical cancer
44	151920	20	27100000	28400000	Amplification	E2F1	Cervical cancer
45	151921	20	27100000	28400000	Amplification	GSS	Cervical cancer
46	151922	20	27100000	28400000	Amplification	KIF3B	Cervical cancer
47	151923	20	27100000	28400000	Amplification	POFUT1	Cervical cancer
48	151924	20	27100000	28400000	Amplification	TPX2	Cervical cancer
49	153446	20	37100000	41100000	Gain	AIB1	Cervical cancer
50	153736	20	41100000	49200000	Amplification	ADNP	Cervical cancer

Sources

Expression for Cervical Cancer

Search GEO for disease gene expression data for Cervical Cancer.

Sources

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	Human papillomavirus infection	hsa05165
2	Viral carcinogenesis	hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 52)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.99	CCND1 FGFR3 HRAS PIK3CA PTEN TP53
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.87	CCND1 HRAS PIK3CA PTEN SMAD4 STAT3
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.77	CCND1 HRAS PIK3CA PTEN SMAD4 TP53
4	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.74	FGFR3 HRAS PIK3CA PTEN TP53
5	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.73	HRAS PIK3CA PTEN STAT3 TP53
6	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.71	CCND1 FGFR3 HRAS PIK3CA PTEN STAT3
7	Pathways in cancer ³⁷	12.64	CCND1 FGFR3 HRAS PIK3CA PTEN SMAD4
8	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.55	CCND1 HRAS PIK3CA SMAD4 STAT3 TP53
9	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.53	FGFR3 HRAS PIK3CA PTEN TP53
10	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.51	CCND1 HRAS PIK3CA PTEN STAT3
11	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.5	CCND1 HRAS PIK3CA STAT3 TP53
12	HTLV-I infection ³⁷	12.44	CCND1 HRAS PIK3CA SMAD4 TP53
13	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.43	FGFR3 HRAS PIK3CA TP53
14	Kaposi's sarcoma-associated herpesvirus infection ³⁷ Show member pathways Hepatitis B ³⁷	12.43	CCND1 HRAS PIK3CA PTEN SMAD4 STAT3
15	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁷ AMPK Signaling Pathway ⁶⁷	12.42	CCND1 HRAS PIK3CA TP53
16	Development A3 receptor signaling ²² Show member pathways Development A1 receptor signaling ²² G-protein signaling G-Protein alpha-q signaling cascades ²²	12.33	CCND1 HRAS PIK3CA STAT3
17	Viral carcinogenesis ³⁷	12.31	CCND1 HRAS PIK3CA STAT3 TP53
18	Colorectal Cancer Metastasis ⁶⁴	12.2	CCND1 SMAD4 STAT3 TP53
19	Kit receptor signaling pathway ¹ Show member pathways IL-3 Signaling Pathway ¹ Signaling events mediated by Stem cell factor receptor (c-Kit) ¹	12.19	HRAS PIK3CA PTEN STAT3
20	Signaling by FGFR2 in disease ⁶⁶ Show member pathways FGFR2 mutant receptor activation ⁶⁶ Signaling by FGFR in disease ⁶⁶ Signaling by FGFR2 IIIa TM ⁶⁶	12.18	FGFR3 HRAS PIK3CA STAT3
21	Cellular senescence (KEGG) ³⁷	12.18	CCND1 HRAS PIK3CA PTEN TP53
22	Proteoglycans in cancer ³⁷	12.18	CCND1 HRAS MIR21 PIK3CA STAT3 TP53
23	Integrated Breast Cancer Pathway ¹	12.16	CCND1 PTEN SMAD4 TP53
24	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²² PDGF Pathway ¹	12.15	HRAS PIK3CA PTEN STAT3
25	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	12.1	FGFR3 HRAS PIK3CA SMAD4 STAT3
26	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.1	CCND1 HRAS PIK3CA PTEN STAT3
27	Hepatitis C ³⁷	12.09	HRAS PIK3CA STAT3 TP53
28	AKT Signaling Pathway ⁶⁷	12.09	CCND1 FGFR3 HRAS PIK3CA PTEN TP53
29	Signaling pathways regulating pluripotency of stem cells ³⁷	12.05	FGFR3 HRAS PIK3CA SMAD4 STAT3
30	Sphingolipid signaling pathway ³⁷	12.03	HRAS PIK3CA PTEN TP53
31	Thyroid hormone signaling pathway ³⁷	12.02	CCND1 HRAS PIK3CA TP53
32	Glioblastoma Multiforme ⁶⁴	11.99	CCND1 HRAS PTEN TP53
33	Development IGF-1 receptor signaling ²² Show member pathways Signal transduction AKT signaling ²²	11.98	CCND1 HRAS PIK3CA PTEN TP53
34	Senescence and Autophagy in Cancer ¹	11.96	HRAS PTEN SMAD4 TP53
35	Small cell lung cancer ³⁷	11.89	CCND1 PIK3CA PTEN TP53
36	Androgen receptor signaling pathway ¹	11.88	CCND1 PTEN SMAD4 STAT3
37	FGFR1 mutant receptor activation ⁶⁶ Show member pathways Signaling by cytosolic FGFR1 fusion mutants ⁶⁶ Signaling by FGFR1 in disease ⁶⁶ Signaling by plasma membrane FGFR1 fusions ⁶⁶	11.84	HRAS PIK3CA STAT3
38	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.83	CCND1 HRAS PIK3CA SMAD4 STAT3
39	Bladder cancer ³⁷ ¹	11.77	CCND1 FGFR3 HRAS TP53
40	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.77	CCND1 HRAS PIK3CA PTEN SMAD4 STAT3
41	MicroRNAs in cancer ³⁷	11.75	CCND1 FGFR3 HRAS MIR21 MIR214 PIK3CA
42	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.72	HRAS PIK3CA PTEN TP53
43	Human Thyroid Stimulating Hormone (TSH) signaling pathway ¹	11.71	HRAS PIK3CA STAT3
44	Neurotrophic factor-mediated Trk receptor signaling ¹ Show member pathways Signalling to STAT3 ⁶⁶ TRKA activation by NGF ⁶⁶	11.66	CCND1 PIK3CA STAT3
45	TGF-beta Receptor Signaling (WikiPathways) ¹	11.63	HRAS SMAD4 STAT3
46	Copper homeostasis ¹	11.59	CCND1 PIK3CA PTEN TP53
47	PDGFR-beta signaling pathway ¹	11.58	HRAS PIK3CA PTEN STAT3
48	Hepatitis C and Hepatocellular Carcinoma ¹	11.53	CCND1 SMAD4 STAT3 TP53
49	DNA Damage Response (only ATM dependent) ¹	11.49	CCND1 HRAS PIK3CA PTEN SMAD4 TP53
50	Central carbon metabolism in cancer ³⁷	11.47	FGFR3 HRAS PIK3CA PTEN TP53

Sources

GO Terms for Cervical Cancer

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.78	FGFR3 HRAS MIR21 PTEN
2	positive regulation of gene expression	GO:0010628	9.65	HRAS MIR21 PTEN STAT3 TP53
3	cell proliferation	GO:0008283	9.55	HRAS PTEN SMAD4 STAT3 TP53
4	interleukin-6-mediated signaling pathway	GO:0070102	9.52	SMAD4 STAT3
5	negative regulation of cardiac muscle hypertrophy	GO:0010614	9.51	MIR21 SMAD4
6	negative regulation of ERK1 and ERK2 cascade	GO:0070373	9.5	MIR21 PTEN SMAD4
7	regulation of mitochondrial membrane permeability	GO:0046902	9.49	STAT3 TP53
8	mitotic G1 DNA damage checkpoint	GO:0031571	9.46	CCND1 TP53
9	response to leptin	GO:0044321	9.43	CCND1 STAT3
10	positive regulation of cell proliferation	GO:0008284	9.43	CCND1 FGFR3 HRAS MIR21 PTEN STAT3
11	cellular response to leptin stimulus	GO:0044320	9.4	PTEN STAT3
12	positive regulation of metalloendopeptidase activity	GO:1904685	9.37	MIR21 STAT3
13	negative regulation of cell proliferation	GO:0008285	9.17	HRAS MIR21 MIR214 PTEN SMAD4 STAT3

Sources

Sources for Cervical Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Cervical Cancer

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Classifications:

External Ids:

Summaries for Cervical Cancer

Related Diseases for Cervical Cancer

Diseases in the Cervical Cancer family:

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Cervical Cancer:

Symptoms & Phenotypes for Cervical Cancer

Clinical features from OMIM:

Human phenotypes related to Cervical Cancer:

UMLS symptoms related to Cervical Cancer:

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Cervical Cancer:

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: 63

FDA approved drugs:

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer

Anatomical Context for Cervical Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

MalaCards organs/tissues related to Cervical Cancer:

Publications for Cervical Cancer

Articles related to Cervical Cancer:

Genes for Cervical Cancer

Genes related to Cervical Cancer (8 elite genes):

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

ClinVar genetic disease variations for Cervical Cancer:

Copy number variations for Cervical Cancer from CNVD:

Expression for Cervical Cancer

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

GO Terms for Cervical Cancer

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

Sources for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: ⁶³